Early Cancer Detection: Will New Screening Technology Disrupt Cancer Care?
The emergence of multi-cancer blood tests for early detection is captivating investors and driving multi-billion-dollar acquisitions. Companies such as GRAIL, Thrive Earlier Detection and Guardant are predicting revolutionary change in the way cancer is diagnosed and treated. The biggest hurdle, however, may be coaxing health care systems and health insurers to join the revolution.
You may also be interested in...
Grail Launches Galleri Multi-Cancer Test In US; Future Of Merger With Illumina Is Still Uncertain
The company launched the lab test in the US. New results from PATHFINDER trial showed an earlier version of Galleri can detect many types of cancer, including early-stage cancer that has yet to metastasize.
Guardant Health, Roche’s Foundation Medicine Receive FDA Companion Diagnostic Nods
Roche’s Foundation Medicine still leads Guardant Health in terms of total companion-diagnostic US FDA approvals as both companies announced new PMA supplements.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class Of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.